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Abstract
Introduction
Extracellular vesicles (EV) are shed from a broad variety of cells and play an important role
in activation of coagulation, cell to cell interaction and transport of membrane components.
They are usually measured as circulating EV in peripheral blood (PB) and other body fluids.
However, little is known about the distribution, presence and impact of EV and their subpop-
ulations in bone marrow (BM). In our study, we focused on the analysis of different EV sub-
types in human BM as compared to EV subsets in PB.
Methods
EV in BM and PB from 12 healthy stem cell donors were measured by flow-cytometry using
Annexin V and cell-specific antibodies for hematopoietic stem cells, leucocytes, platelets,
red blood cells, and endothelial cells. Additionally, concentrations of tissue factor-bearing
EV were evaluated.
Results
High numbers of total EV were present in BM (median value [25–75 percentile]: 14.8 x109/l
[8.5–19.3]). Non-significantly lower numbers of total EV were measured in PB (9.2 x109/l
[3.8–14.5]). However, distribuation of EV subtypes showed substantial differences between
BM and PB: In PB, distribution of EV fractions was similar as previously described. Most EV
originated from platelets (93.9%), and only few EV were derived from leucocytes (4.5%),
erythrocytes (1.8%), endothelial cells (1.0%), and hematopoietic stem cells (0.7%). In con-
trast, major fractions of BM-EV were derived from red blood cells or erythropoietic cells
(43.2%), followed by megacaryocytes / platelets (27.6%), and by leucocytes as well as their
progenitor cells (25,7%); only low EV proportions originated from endothelial cells and
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hematopoietic stem cells (2.0% and 1.5%, respectively). Similar fractions of tissue factor—
bearing EV were found in BM and PB (1.3% and 0.9%).
Conculsion
Taken together, we describe EV numbers and their subtype distribution in the BM compart-
ment for the first time. The tissue specific EV distribution reflects BM cell composition and
favours the idea of a BM–PB barrier existing not only for cells, but also for EV.
Introduction
Initially described as cell dust in 1946 [1], extracellular vesicles (EV) are membrane vesicles
released from different cell types. Circulating EV in blood are derived from all vascular and
blood cells [2] and differ in size from 0,1 to 1 μm. They contain a mixture of lipids, proteins
and surface markers, which reflects the composition of their cellular origin [3]. EV formation
is triggered by apoptosis and cell activation and is known to have various physiological and
pathological functions such as transport of membrane components, activation of inflamma-
tion and stimulation of coagulation [4]. It has become more and more evident that circulating
EV can serve as surrogate markers for diseases like diabetes [5], hypertension [6], arterial
thrombosis [7], or sepsis [8]. Moreover, EV seem to be involved in oncogenesis, tumor pro-
gression, and pathogenesis of metastasis in cancer patients [9,10,11]. EV have been sucessfully
utilized as diagnostic biomarkers in patients with changiocarcinoma, hepatocellular and lung
cancers [12,13,14]. Furthermore, some cancer cells use EV for export of antineoplastic drugs
mediating drug resistenance [15].
Recently, EV have also been detected in other tissues and body fluids. For example, high
levels of EV were detected in cerebrospinal fluid in patients after brain injury [16]. Gyo¨rgy
et al. found EV in joint fluid in different concentrations and membrane patterns, dependent
on the underlying arthropathy [17].
However, little is known about EV in the BM compartment. BM is the major hematopoietic
organ and a primary lymphoid tissue, responsible for the production and maturation of eryth-
rocytes, granulocytes, monocytes, lymphocytes and platelets. There is strict control of cell
migration from BM into PB and vice versa. The endothelium of BM sinuses is a continuous
layer which contains a selective cellular transport system that serves as the marrow-blood bar-
rier. Our data suggest that this barrier is relevant also for EV.
The aim of this study was to detect frequency and composition of EVs in the BM compart-
ment of healthy individuals in comparison to the corresponding EV fraction in PB.
Patients and methods
Study population and trial design
12 healthy hematopoetic stem cells donors were recruited (6 women, 6 men, median age 42
years (range: 21–56 years) between April 2011 and January 2012. All of them donated BM for
family members undergoing hematopoietic stem cell transplantation. Donors were healthy
without diagnosis of chronic disease (especially hepatitis or HIV were excluded). PB counts
were normal for each donor. PB and BM specimens were taken during routine sampling.
The Human Investigation Review Board of the Ludwig-Maximilian-University Munich
approved the study. Signed written informed consent for the study was obtained from all
donors.
Detection of extracellular vesicles in human bone marrow
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Blood sampling and assessment
PB samples (5ml) were taken from donors via hollow needle (20 gauge) without swelling to
avoid platelet activation. Paired 5 ml samples of aspirated BM blood were harvested by low
negative pressure using a large-core Jamshidi needle (11 gauge). Samples from both compart-
ments were centrifuged for 20 minutes at 1,550 × g within 15 minutes after sampling, plamsa
fraction was kept in liquid nitrogen for 15 minutes to stabilize the samples and avoid uncon-
trolled EV formation. Samples were then stored at– 80˚C.
Isolation of extracellular vesicles
Samples were thawed carefully over approximately one hour and isolated regarding to the
description by Berckmans RJ et al. [18]: after centrifugation of 250 μl plasma for 30 minutes
with a centrifugal force of 18,890 x g, 225 μl plasma were removed. EV were resuspended after
addition of 225 μl of citrate buffer (3,2% tri-natrium-citrate) and centrifuged again for 30 min-
utes with 18,890 x g. After removal of 225 μl of EV free supernatant, 75 μl citrate buffer was
added and the EV pellet was resuspended again. For detection of EV bearing cell-specific anti-
gens, 5 μl of suspension were incubated for 15 minutes with 5 μl of APC-labeled annexin V
(IQ products, Groningen, The Netherlands) in the dark at room temperature together with a
cell-specific antibody for double staining: PE-labeled anti-CD45 (BD Pharmingen, San Diego,
USA) for leucocyte-derived EV, FITC-labeled anti-CD235a (DakoCytomation, Denmark) for
erythrocyte-derived EV, PE-labeled anti-CD34 (BD Pharmingen, San Diego, USA) for stem
cell-derived EV, PE-labeled anti-CD62E (BD Pharmingen, San Diego, USA) for endothelium-
derived EV or PE-labeled anti-CD142 (BD Pharmingen, San Diego, USA) for EV carrying tis-
sue factor. For detection of platelet-derived EV, triple-staining was used: APC-labeled annexin
V (IQ products, Groningen, The Netherlands) together with FITC-labeled anti-CD61 (Dako-
Cytomation, Denmark) as common platelet marker and, additionally, platelet activation
marker PE-labeled anti-CD62P (Immunotech, Marseille, France) or alternativly PE-labeled
anti-CD63 (Immunotech, Marseille, France). The reaction was stopped with 900 μl of calcium
buffer (2,5 mmol/l) except for the annexin V control, which was filled up with 900μl citrate-
containing PBS. EV were resuspended before flow cytometry analysis.
Analysis of EV
All samples were analysed with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg,
Germany) running the Cell Quest Software (Becton Dickinson, San Jose, CA, USA). The flow
cytometer was run on high pressure. Forward (FSC) and sideward scatter (SSC) were set to
logarithmic gain and cell derived EV were identified via simultaneous binding to annexin V
and markers of EV origin cells. All samples were analysed for one minute. The volume ana-
lysed in one minute (V; approximately 50–80 μl) was determined each day before analysis by
taking the weight of a sample (aqua dest) before and after analysis. The gating strategy for iso-
lation of EV is shown in Fig 1. The number of EV/μl of plasma was determined by using fol-
lowing formula: EV/l = N x (100μl/5μl) x (950μl/V) x 106/250μl) according to Berckmans RJ
et al [11] (N = absolute number of EV determined by FACS analysis; 100μl = total volume of
washed EV suspension; 5 μl = pellet used for analysis; 950μl = total volume before analysis (pel-
let + antibodies + buffer); 250μl = original volume of the sample before isolation of EV).
Statistical analysis
Results are reported as median and interquartile range, if not stated otherwise. Variables were
tested by the paired non-parametic Wilcoxon test, and Spearman test for correlation
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coefficients. Statistical analyses were performed using the Statistical Package for the Social
Sciences SPSS for Windows 20.0 (SPSS Inc., Chicago, IL, USA). All p-values are two-sided,
p-values <0.05 are considered significant. Due to the exploratory nature of our analyses, no
adjustment for multiple testing was undertaken.
Fig 1. Gating strategy for identification of microparticle (EV). First, EV were identified by their dimension as described by Nieuwland et al.
[19] (a). As negative control, EV were double stained with control antibody IgG plus annexin V in a Ca2+-free buffer (b). After addition of Ca2+,
annexin V binds with high specificity and sensitivity to EV (c; R3). Double staining with annexin V and a cell-specific antibody identifies EV
subpopulations (d; R4).
https://doi.org/10.1371/journal.pone.0207950.g001
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Results
Total EV
In BM of healthy humans (BM-EV), a high total number of annexin V-binding EV was
detected without reaching statistically significant differences compared to EV in PB (9.2 x109/l
[3.8–14.5] vs. 14.8 x109/l [8.5–19.3], p = 0.060). Data of total EV and their subset distribuation
are shown in Fig 2, exact values are given in supplement (S1 Table). No statistically significant
correlations were found between BM-EV and PB-EV or their corresponding subpopulations.
Pairwise data of total BM-EV versus PB-EV and their subtypes from each donor are also
shown in supplement (S1 Fig).
Erythrocyte-derived EV (EryEV)
EryEV were identified as CD235a positiv EV and represented the major sub-fraction (43.2%)
of all detected EV in BM. In contrast, only a small portion of EryEV was present in PB (1.8%).
Platelet-derived EV (PEV)
CD61-exposing PEV (27.6%) constituted the second largest EV-fraction in BM. In PB, PEV
represented the major subgroup (93.9%) of all measured circulating EV. The portion of activa-
tion marker CD63—bearing PEV was nearly half in the BM compartment; in contrast, only a
small fraction of PEV in PB was found to be CD63 positive. However, the second activation
maker CD62P was discovered on approximately 5% of PEV in both compartments.
Leucocyte-derived EV (LEV)
25.7% EV in BM were CD45 positive. In contrast, CD45-positive EV in PB were found only in
4.5%.
Endothelial EV (EEV)
The proportion of CD62E-positive EEV was low in BM (2%) and even less in PB (1%).
Haematopoetic stem cell derived EV (HEV)
CD34 positive HEV were detected with low frequency in PB (0.7%) and with higher frequency
in BM (1.5%).
Tissue factor bearing EV (TfEV)
1.3% of total EV in BM were CD142 positive, 0.9% in PB.
Discussion
Total EV numbers in BM was higher than in PB. This difference was not statistically significant
most likely due to low sample size of 12 donors. EV mainly arise during cell activation or cell
death and carry antigens from their cells of origin. Thus, it is not surprising to detect a consid-
erable high count of EV in human BM, a compartment with high cell proliferation. One of the
major findings of this study is the fundamentally different distribution of EV subtypes in BM
compared to circulating EV in PB possibly reflecting different cell composition of these two
compartments. Assuming that EV synthesis and function in BM is equal or just similar to PB,
it is highly possible that EV play a pivotal role in cell to cell—communication. As EV contain
parts of the outer membrane and the cytoplasm of their cells of origin, they may present a
broad variety of cell adhesion and signalling molecules on their surface. Cells can even mediate
Detection of extracellular vesicles in human bone marrow
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intercellular communication by secreting EV enriched with different RNA species [20]. As we
have found high levels of EV in BM, they might be of importance for regulation und interac-
tion of hematopoiesis and immune functions inside BM. Furthermore, EV play a major role in
Fig 2. Total EV and their subsets in BM versus PB. X-axis: compartment of bone marrow (BM) versus compartment of peripheral blood
(PB). Y-axis: Concentration of total EVs and respective subpopulations; EryEV: EV derived from erythrocytes or their progenitor cells, LEV:
EV derived from leukocytes or their progenitor cells, PEV: EV derived from platelets or megakaroycytes, EEV: EV derived from endothelium
cells, HEV: EV derived from hematopoetic stem cells, TfEV: EV bearing tissue factor. Level of significance p< 0.05.
https://doi.org/10.1371/journal.pone.0207950.g002
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activation of plasmatic coagulation by presenting a large activated phospholipid surface with
binding sites for several different coagulation factors [21,22]. This important function becomes
obvious in patients with Scott syndrome suffering from a haemophilia-like bleeding disorder
due to a high-grade deficiency of platelet-derived EV [23]. Conversely, elevated levels of circu-
lating EV are associated with thrombotic events [24]. Following these clinical observations, co-
transfusion of EV together with stem cells during BM transplantation leads to a temporary
increase of circulating EV in transplanted patients which is considered to be causative for
venous thrombotic complications [25]. Particularly, a higher incidence of catheter associated
thrombotic event is described during the first weeks of transplantation [26].
In our investigation, the largest subfraction of EV in BM was found to be derived from
erythrocytes and further erythropoetic cells. This reflects the high abundance and proliferation
/ differentiation activity of erythroblastic cells. Erythropoesis occurs in distinct cellular units,
called erythroblastic islands and seems to be accompanied by high rate of shedded EV carring
CD279 on their surface. Hence, EV are involved in cell maturation of erytroid cells e.g. they
are postulated to have an important function during terminal differentiation of reticulocytes
into erythrocytes. EV and other microvesicles are thought to remove cellular molecules or
organelles no longer required at this step of erythroid differentiation [27,28]. In contrast, we
detected much lower EryEV levels in PB indicating that adult red blood cells release only a
very small number of EV. This finding is in line with other reports demonstrating that mature
erythrocytes shed almost no EV under physiological conditions. Also, patients with infections
or even septic infections don´t exhibit elevated circulating EryEV numbers. Elevated EryEV
levels have only been described under distinct medical conditions like in patients with sickle
cell disease [29], in preeclamptic women [30], and in patients with acute graft-versus-host dis-
ease or with microangiopathy [31].
The second largest EV fraction in BM was CD61 positive. It may surprise that approxi-
mately one quarter of EV orginates from platelets whereas more than 90% of EV are derived
from platelets in PB. This difference could be explained by the fact that megakaryopoiesis
occurs adjacent to the sinus endothelium. Platelets and probably related CD61-positive EV are
released together directly into the blood stream [32]. This might cause the relatively low levels
of PEV in BM. However, our data would also support the hypothesis that at least a part of PEV
in PB originate from megakaryocytes, as they have direct access to the blood stream and can-
not be distinguished from EV derived from circulating platelets [33]. This, however, does not
exclude that some CD61-positive EV are released from megakaryocytes. Only a low portion of
PEV was positive for the activation marker CD62P in both investigated compartments. The
other activation marker CD63 was detected on PEV at also similar low level in PB. Surpris-
ingly, CD63 accounted for almost half of CD61-positive EV in BM. CD63 is a member of the
tetraspanin family commonly used as a marker for strong platelet activation. It is expressed on
the inner surface of platelet lysosomes. However, it is not confined to platelets: CD63 is present
in late endosomes and lysosomes of other cell types and participates in a variety of cellular pro-
cesses, like cell activation, adhesion, and differentiation. In late endosomes, CD63 is enriched
on the intraluminal vesicles, which by activation are secreted through fusion with the plasma
membrane [34, 35].
Another quarter of BM-EV belongs to cells from lymphopoiesis and myeloid cells. In PB,
only a small number of EV was CD45 positive which could possibly be explained by the analy-
sis of healthy donors in our study population. Elevated numbers of leucocyte derived EV can
be mainly found after activation of white blood cells like described for example in patients
with atherosclerosis [36] or with severe infection like Shiga-toxin mediated haemolytic uremic
syndrome [37].
Detection of extracellular vesicles in human bone marrow
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Endothelial derived EV represent only a small part of al EV. However, we measured nearly
four times higher concentrations of this EV subtype in BM compared to PB, In PB, endothelial
cell EV are commonly regarded a biological marker of endothelial activation or apoptosis [38].
In the Framingham Heart study circulating endothelium-derived microparticles were associ-
ated with cardiometabolic risk factors [39]. Furthermore, either elevated concentration or
altered composition of this EV subtype could be found in a broad variety of diseases like vascu-
litis [40], acute coronary syndrom [41], mitral valve disease [42] or thrombotic thrombocyto-
penic purpura [43]. The relatively high EEV levels in BM of healthy donors might reflect the
fact that endothelium is highly abundant and active in BM.
A small number of BM-EV orginates from CD34-positive hematopoietic stem cells. This
EV subtype is even less frequent in PB. The source of circulating hematopoietic stem cell EV,
however, is not clear: either they are released from circulating stem cells or they are able to
penetrate the blood-marrow barrier.
Tissue factor (TF, CD142) is the major initiator of the extrinsic coagulation cascade and is
mainly expressed on non-vascular cells like epidermis, renal glomeruli or smooth muscle cells.
In PB, main reservoir of circulating TF is the pool of CD142-positive EV [44]. Enhanced levels
of TF-carrying EV have been observed in cancer patients, in patients with unstable angina
[45], and in patients with severe infections/sepsis. In our study, TF-positive EV were measured
at low frequency in PB of healthy humans. TF-EV abundance was slightly higher in BM.
These presenting findings of our study are restricted by some limitations. First, the number
of investigated individuals is small depending on the fact that our investigation was planned as
a basic research project to provide evidence of the existence of EV in BM. Furthermore, we
were not able to correlate BM-EV with counts of their mother cells in BM because, from an
and ethical point of view, it is not possible to take a bone marrow biopsy from a healthy donor
for histological analyses not required for the stem cell donation itself. Lastly, our analyses were
restricted to an EV size of 500 nm due to the technique of flow cytometry. Recent published
data from the ISTH-SSC-VB Working group [46] revealed and discussed this limitation by
comparing 46 different types of flow cytometer. Thus, exosomes and other smaller EV are not
detectable by the applied method of flow cytometry.
In summary, our data firstly demonstrate a high level of EV in BM with a fundamental dif-
ferent subgroup composition compared to PB. This finding suggests that the physiological bar-
rier between BM and PB exists not only for cells but also for EV.
Supporting information
S1 Table. Numbers of EV in bone marrow vs. peripheral blood. Numbers are given as mean
values and interquartile range. EryEV: EV from erythrocytes / erythropoetic cells. PEV: EV from
megacaryocytes / platelets. LEV: EV from leucocytes / leucocytic progenitor cells. EEV: EV from
endothelial cells. HEV: EV from hematopoetic stem cells. TfEV: tissue factor—bearing EV.
(DOCX)
S2 Table. Data file. Measured EV data from al donors in N/μl.
(PDF)
S1 Fig. Total EV and their subsets. Data presented as EV concentrations in bone marrow ver-
sus peripheral blood from each donor. EryEV: EV derived from erythrocytes or their progeni-
tor cells, LEV: EV derived from leukocytes or their progenitor cells, PEV: EV derived from
platelets or megakaroycytes, EEV: EV derived from endothelium cells, HEV: EV derived from
hematopoetic stem cells, TfEV: EV bearing tissue factor.
(TIF)
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